Lilly Adds Suicide Warning to Strattera

CHICAGO (Reuters) - Eli Lilly and Co. on Thursday said it will add strong warnings to its label for Strattera (atomoxetine), used to treat attention-deficit/hyperactivity disorder, including the risk of suicidal thoughts among children and adolescents.

Strattera will carry a "black box" warning, the strongest required by U.S. regulators.

Lilly said there were no suicides among children, adolescents or adults taking the medication during Strattera clinical trials, but there was one suicide attempt in a patient taking the drug.